Last reviewed · How we verify
Shilpa Grover, MD, MPH — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Prednisone Taper | Prednisone Taper | marketed | Corticosteroid (glucocorticoid) | Glucocorticoid receptor (GR) | Immunology, Rheumatology, Endocrinology |
Therapeutic area mix
- Immunology, Rheumatology, Endocrinology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- Benazir Bhutto Hospital, Rawalpindi · 1 shared drug class
- Berinstein, Jeffrey · 1 shared drug class
- Celgene · 1 shared drug class
- Children's Hospital of Philadelphia · 1 shared drug class
- Chong Kun Dang Pharmaceutical · 1 shared drug class
- Ain Shams University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shilpa Grover, MD, MPH:
- Shilpa Grover, MD, MPH pipeline updates — RSS
- Shilpa Grover, MD, MPH pipeline updates — Atom
- Shilpa Grover, MD, MPH pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shilpa Grover, MD, MPH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shilpa-grover-md-mph. Accessed 2026-05-16.